- Home
- ABOS vs CMPX Comparison
ABOS vs CMPX Comparison
Compare ABOS & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABOS
- CMPX
- Stock Information
- Founded
- ABOS 1996
- CMPX 2014
- Country
- ABOS United States
- CMPX United States
- Employees
- ABOS N/A
- CMPX N/A
- Industry
- ABOS Biotechnology: Pharmaceutical Preparations
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- ABOS Health Care
- CMPX Health Care
- Exchange
- ABOS Nasdaq
- CMPX Nasdaq
- Market Cap
- ABOS 99.1M
- CMPX 214.6M
- IPO Year
- ABOS 2021
- CMPX N/A
- Fundamental
- Price
- ABOS $1.56
- CMPX $2.00
- Analyst Decision
- ABOS Strong Buy
- CMPX Strong Buy
- Analyst Count
- ABOS 3
- CMPX 4
- Target Price
- ABOS $9.33
- CMPX $13.75
- AVG Volume (30 Days)
- ABOS 379.4K
- CMPX 1.8M
- Earning Date
- ABOS 11-12-2024
- CMPX 11-12-2024
- Dividend Yield
- ABOS N/A
- CMPX N/A
- EPS Growth
- ABOS N/A
- CMPX N/A
- EPS
- ABOS N/A
- CMPX N/A
- Revenue
- ABOS N/A
- CMPX $850,000.00
- Revenue This Year
- ABOS N/A
- CMPX N/A
- Revenue Next Year
- ABOS N/A
- CMPX $613.39
- P/E Ratio
- ABOS N/A
- CMPX N/A
- Revenue Growth
- ABOS N/A
- CMPX N/A
- 52 Week Low
- ABOS $1.54
- CMPX $0.77
- 52 Week High
- ABOS $5.09
- CMPX $2.68
- Technical
- Relative Strength Index (RSI)
- ABOS 30.29
- CMPX 65.48
- Support Level
- ABOS $1.69
- CMPX $1.43
- Resistance Level
- ABOS $1.88
- CMPX $2.68
- Average True Range (ATR)
- ABOS 0.13
- CMPX 0.24
- MACD
- ABOS -0.00
- CMPX 0.06
- Stochastic Oscillator
- ABOS 4.88
- CMPX 46.87
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.